Dasiglucagon (Zegalogue)

Peptide

Dasiglucagon is a 29-amino acid glucagon analog with 7 amino acid substitutions for improved aqueous stability. FDA-approved March 2021 for severe hypoglycemia in patients 6+ with diabetes. First ready-to-use aqueous glucagon formulation (no reconstitution needed). Phase 3 trial (n=170): Median time to recovery 10 min vs 40 min placebo (P<0.001). 99% achieved plasma glucose recovery within 15 min. Also being studied for congenital hyperinsulinism.

Quick Answer

What it is

Dasiglucagon is a 29-amino acid glucagon analog with 7 amino acid substitutions for improved aqueous stability. FDA-approved March 2021 for severe hypoglycemia in patients 6+ with diabetes.

Key findings

Grade A: Time to Glucose Recovery (Adult)
Grade A: 15-Minute Recovery Rate
Grade A: Pediatric Efficacy

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Dasiglucagon (Zegalogue)

Quick Facts: Dasiglucagon (Zegalogue)

Best Evidence:Grade A
Conditions Studied:1
Research Outcomes:7
Grade A Findings:3
Grade B Findings:3

1 conditions · 7 outcomes

Detailed Outcomes

Time to Glucose Recovery (Adult)

Phase 3 trial (n=170 T1DM adults): Median time to plasma glucose recovery 10 min with dasiglucagon vs 40 min placebo (P<0.001). Similar to reconstituted glucagon (12 min). Led to FDA approval March 2021.

large↓Improves

15-Minute Recovery Rate

Phase 3 adult trial: 99% (all but 1 patient) achieved plasma glucose recovery within 15 min with dasiglucagon vs only 2% placebo (P<0.001). Similar to reconstituted glucagon (95%).

large↑Improves

Pediatric Efficacy

Phase 3 pediatric trial (children/adolescents with T1DM): Rapid and effective treatment of insulin-induced hypoglycemia. Median time to recovery comparable to adults. Safe in ages 6 years and older.

large↑Improves

Ready-to-Use Formulation Benefit

First glucagon in ready-to-use aqueous formulation requiring no reconstitution. Eliminates mixing errors and delays in emergency situations. Stable at room temperature for 12 months.

moderate↑Improves